Cameron Hunter

Dr. Cameron Hunter

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2002 in Chest
Verified
Journal Article
Closed access
CHCameron Hunter
Cameron Hunter
CBChristopher E. Brightling
Christopher E. Brightling
GWGerrit Woltmann
Gerrit Woltmann
AWAndrew J. Wardlaw
Andrew J. Wardlaw
IPIan D. Pavord
Ian D. Pavord

10 September 2024 in American Journal of Hematology
Verified
Journal Article
Closed access
TBTalha Badar
Talha Badar
RNRavi Narra
Ravi Narra
AMAlice S. Mims
Alice S. Mims
MHMichael G. Heckman
Michael G. Heckman
RSRory M. Shallis
Rory M. Shallis
MLMark R Litzow
Mark R Litzow

16 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
CHCameron Hunter
Cameron Hunter
AIAnnie Pearl Im
Annie Pearl Im
RSRory M Shallis
Rory M Shallis
Mutations in TP53 inhibit p53 protective behaviors including cell cycle arrest, DNA damage repair protein recruitment, and apoptosis. The ubiquity of p53 in genome-stabilizing functions leads to an aberrant tumor microenvironment in TP53-mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Profound immunosuppression mediated by myeloid-derived suppressor cells, the upregulation of cytokines and cell-surface receptors on leukemic cells, the suppression of native immune regulator cells, and metabolic aberrations in the bone marrow are features of the TP53-mutated AML/MDS marrow microenvironment. These localized changes in the bone marrow microenvironment (BMME) explain why traditional therapies for MDS/AML, including chemotherapeutics and hypomethylating agents, are not as effective in TP53-mutated myeloid neoplasms and demonstrate the dire need for new treatments in this patient population. The unique pathophysiology of TP53-mutated disease also provides new therapeutic approaches which are being studied, including intracellular targets (MDM2, p53), cell-surface protein biologics (immune checkpoint inhibitors, BiTE therapy, and antibody–drug conjugates), cell therapies (CAR-T, NK-cell), signal transduction pathways (Hedgehog, Wnt, NF-κB, CCRL2, and HIF-1α), and co-opted biologic pathways (cholesterol synthesis and glycolysis). In this review, we will discuss the pathophysiologic anomalies of the tumor microenvironment in TP53-mutant MDS/AML, the hypothesized mechanisms of chemoresistance it imparts, and how novel therapies are leveraging diverse therapeutic targets to address this critical area of need.

29 October 2025 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
CHCameron Hunter
Cameron Hunter
WCWei Cheng
Wei Cheng
JBJan Bewersdorf
Jan Bewersdorf
PBPrajwal Boddu
Prajwal Boddu
SBSabrina Browning
Sabrina Browning
RSRory Shallis
Rory Shallis
Patients treated with intensive induction therapy for acute myeloid leukemia (AML) traditionally remain admitted until count recovery, however, select patients may be safe for 'early' discharge. We evaluated sequential patients with newly diagnosed AML treated with intensive induction at Yale Cancer Center from December 2016 to January 2024 and eligible for an early discharge program (EDP). Amongst 185 patients, 99 (53.5%) were discharged with an absolute neutrophil count (ANC) <0.5 x 103/µL. An ANC ≤0.1 x 103/µL at discharge (N = 54) was used to define patients furthest from hematologic recovery. These patients had fewer inpatient days accounting for re-admissions (23%) before count recovery (23.5 vs 28.0 days, p = 0.0003). Most readmissions (92%) were for febrile neutropenia and uncomplicated. Ultimately, there were no differences in 90-day mortality, or median overall survival between patients with ANC ≤0.1 x 103/µL at discharge and non-EDP patients. An EDP is feasible and safe for select patients.

28 November 2025 in Leukemia Research
Verified
Journal Article
Closed access
CHCameron Hunter
Cameron Hunter
ACAndrew Chou
Andrew Chou
HRHeidi Roeder
Heidi Roeder
WEWilliam Eighmy
William Eighmy
JBJan Bewersdorf
Jan Bewersdorf
RSRory Shallis
Rory Shallis